337 related articles for article (PubMed ID: 19412102)
1. Infectious complications of biological therapy.
Haroon N; Inman RD
Curr Opin Rheumatol; 2009 Jul; 21(4):397-403. PubMed ID: 19412102
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.
Keane J; Bresnihan B
Curr Opin Rheumatol; 2008 Jul; 20(4):443-9. PubMed ID: 18525359
[TBL] [Abstract][Full Text] [Related]
3. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.
Vassilopoulos D; Calabrese LH
Curr Opin Rheumatol; 2007 Nov; 19(6):619-25. PubMed ID: 17917544
[TBL] [Abstract][Full Text] [Related]
4. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
Wendling D; Di Martino V; Herbein G
J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
[No Abstract] [Full Text] [Related]
5. Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part I. Risks associated with tumor necrosis factor-alfa antagonists.
Chirch LM; Cataline PR; Dieckhaus KD; Grant-Kels JM
J Am Acad Dermatol; 2014 Jul; 71(1):1.e1-8; quiz 1.e8-9, 10. PubMed ID: 24947698
[TBL] [Abstract][Full Text] [Related]
6. Impact of biologic agents on infectious diseases.
Saketkoo LA; Espinoza LR
Infect Dis Clin North Am; 2006 Dec; 20(4):931-61, viii. PubMed ID: 17118297
[TBL] [Abstract][Full Text] [Related]
7. Soft tissue infections.
Torralba KD; Quismorio FP
Rheum Dis Clin North Am; 2009 Feb; 35(1):45-62. PubMed ID: 19480996
[TBL] [Abstract][Full Text] [Related]
8. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination.
Kavanaugh A
Curr Opin Rheumatol; 2009 Jul; 21(4):419-24. PubMed ID: 19444117
[TBL] [Abstract][Full Text] [Related]
9. Incidence and nature of infectious disease in patients treated with anti-TNF agents.
Raychaudhuri SP; Nguyen CT; Raychaudhuri SK; Gershwin ME
Autoimmun Rev; 2009 Dec; 9(2):67-81. PubMed ID: 19716440
[TBL] [Abstract][Full Text] [Related]
10. mAbs in nonlupus autoimmune rheumatic disease.
Whelan BR; Isenberg DA
Curr Opin Hematol; 2009 Jul; 16(4):280-4. PubMed ID: 19444098
[TBL] [Abstract][Full Text] [Related]
11. [Infectious complications due to immunosuppression in organ transplant patients].
Morelon E; Touraine JL
Rev Prat; 2007 Oct; 57(15):1677-86. PubMed ID: 18080426
[TBL] [Abstract][Full Text] [Related]
12. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.
Calabrese LH; Zein N; Vassilopoulos D
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii18-ii24. PubMed ID: 15479865
[TBL] [Abstract][Full Text] [Related]
13. How to manage infections in the era of biologics?
Saraceno R; Chimenti S
Dermatol Ther; 2008; 21(3):180-6. PubMed ID: 18564248
[TBL] [Abstract][Full Text] [Related]
14. Treatment of rheumatic diseases in patients with HCV and HIV infection.
Galeazzi M; Giannitti C; Manganelli S; Benucci M; Scarpato S; Bazzani C; Caporali R; Sebastiani GD
Autoimmun Rev; 2008 Dec; 8(2):100-3. PubMed ID: 18694850
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis in the age of biologic therapy.
Hernandez C; Cetner AS; Jordan JE; Puangsuvan SN; Robinson JK
J Am Acad Dermatol; 2008 Sep; 59(3):363-80; quiz 382-4. PubMed ID: 18694676
[TBL] [Abstract][Full Text] [Related]
16. Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part II. Screening for patients on tumor necrosis factor-alfa antagonists.
Chirch LM; Cataline PR; Dieckhaus KD; Grant-Kels JM
J Am Acad Dermatol; 2014 Jul; 71(1):11.e1-7; quiz 18-20. PubMed ID: 24947699
[TBL] [Abstract][Full Text] [Related]
17. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
18. [Immunosupression and viral infections in rheumatic diseases].
Vince A; Dusek D
Reumatizam; 2007; 54(2):58-62. PubMed ID: 18351141
[TBL] [Abstract][Full Text] [Related]
19. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
20. [Vaccinations in patients with autoimmune inflammatory rheumatic diseases--EULAR recommendations for pediatric and adult patients].
Müller-Ladner C; Müller-Ladner U;
Med Monatsschr Pharm; 2012 Oct; 35(10):353-64; quiz 365-6. PubMed ID: 23094578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
